The Technology Council of North Dakota (TechND) named Aldevron one of three leading businesses within the technology sector, emphasizing its achievements and contributions to the biotech industry through innovation and expertise.
Aldevron, a global leader in the manufacture of plasmid DNA, mRNA and proteins, has promoted Venkata Indurthi to Vice President of Research and Development (R&D). He will begin this new role immediately and continue reporting to John Ballantyne, Co-founder and Chief Scientific Officer while having direct access to Aldevron’s senior executive team.
As clustered regularly interspaced short palindromic repeats (CRISPR) therapies progress to the clinic, the key CRISPR editing components are primarily being delivered by recombinant virus, RNA, or as ribonucleoprotein (RNP), which is the active complex formed by the guide RNA and Cas9 protein. RNPs have several attractive properties as a delivery format, particularly in the manufacturing of ex vivo cellular therapies, the most rapidly growing segment of the CRISPR therapeutics market.